Invesco’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $405M | Buy |
5,780,299
+995,541
| +21% | +$51.5M | 0.03% | 441 |
|
|
2026
Q1 | $243M | Sell |
4,784,758
-2,244,936
| -32% | -$105M | 0.02% | 625 |
|
|
2025
Q4 | $207M | Sell |
7,029,694
-1,186,469
| -14% | -$32.2M | 0.02% | 663 |
|
|
2025
Q3 | $212M | Buy |
8,216,163
+1,115,131
| +16% | +$31.1M | 0.03% | 642 |
|
|
2025
Q2 | $196M | Buy |
7,101,032
+1,217,408
| +21% | +$32.1M | 0.03% | 639 |
|
|
2025
Q1 | $167M | Buy |
5,883,624
+877,162
| +18% | +$31.1M | 0.03% | 667 |
|
|
2024
Q4 | $208M | Buy |
5,006,462
+979,858
| +24% | +$46.8M | 0.04% | 618 |
|
|
2024
Q3 | $269M | Buy |
4,026,604
+1,486,333
| +59% | +$136M | 0.05% | 477 |
|
|
2024
Q2 | $302M | Sell |
2,540,271
-229,651
| -8% | -$29.1M | 0.06% | 398 |
|
|
2024
Q1 | $295M | Sell |
2,769,922
-139,687
| -5% | -$14.1M | 0.06% | 427 |
|
|
2023
Q4 | $289M | Sell |
2,909,609
-216,419
| -7% | -$18.2M | 0.07% | 382 |
|
|
2023
Q3 | $323M | Buy |
3,126,028
+517,683
| +20% | +$57.7M | 0.09% | 298 |
|
|
2023
Q2 | $317M | Buy |
2,608,345
+291,912
| +13% | +$38.9M | 0.08% | 318 |
|
|
2023
Q1 | $356M | Buy |
2,316,433
+574,362
| +33% | +$94.8M | 0.1% | 265 |
|
|
2022
Q4 | $313M | Buy |
1,742,071
+15,134
| +0.9% | +$2.47M | 0.09% | 304 |
|
|
2022
Q3 | $204M | Sell |
1,726,937
-103,284
| -6% | -$15.7M | 0.07% | 409 |
|
|
2022
Q2 | $261M | Sell |
1,830,221
-298,031
| -14% | -$42.6M | 0.08% | 338 |
|
|
2022
Q1 | $367M | Buy |
2,128,252
+371,311
| +21% | +$62.5M | 0.09% | 276 |
|
|
2021
Q4 | $446M | Buy |
1,756,941
+914,343
| +109% | +$267M | 0.11% | 230 |
|
|
2021
Q3 | $324M | Buy |
842,598
+279,271
| +50% | +$103M | 0.08% | 306 |
|
|
2021
Q2 | $132M | Buy |
563,327
+160,809
| +40% | +$28.7M | 0.03% | 708 |
|
|
2021
Q1 | $52.7M | Sell |
402,518
-75,659
| -16% | -$11M | 0.01% | 1039 |
|
|
2020
Q4 | $50M | Sell |
478,177
-211,307
| -31% | -$21.4M | 0.01% | 1024 |
|
|
2020
Q3 | $48.8M | Sell |
689,484
-2,626,700
| -79% | -$183M | 0.02% | 952 |
|
|
2020
Q2 | $213M | Sell |
3,316,184
-1,328,052
| -29% | -$72.7M | 0.08% | 321 |
|
|
2020
Q1 | $139M | Buy |
4,644,236
+2,162,732
| +87% | +$49.8M | 0.06% | 392 |
|
|
2019
Q4 | $48.5M | Buy |
2,481,504
+787,469
| +46% | +$14M | 0.02% | 1029 |
|
|
2019
Q3 | $27M | Buy |
1,694,035
+1,413,059
| +503% | +$20.9M | 0.01% | 1239 |
|
|
2019
Q2 | $4.11M | Buy |
280,976
+253,421
| +920% | +$5.44M | ﹤0.01% | 2292 |
|
|
2019
Q1 | $561K | Buy |
+27,555
| New | +$511K | ﹤0.01% | 3264 |
|
Other funds holding MRNA
TP
Invesco's MRNA Position: Q2 2026 in Review
Invesco increased its Moderna (MRNA) stake by 21% in Q2 2026, buying an estimated $51.5M and bringing the position to 5,780,299 shares worth $405M. The position accounts for 0.03% of the portfolio, ranked #441.
Invesco first reported a position in MRNA in Q1 2019 and has held it in 30 quarters since. The position peaked at $446M in Q4 2021. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.
- Invesco held 5,780,299 shares of Moderna worth $405M as of Q2 2026.
- Invesco bought 995,541 Moderna shares in Q2 2026, an estimated $51.5M.
- Moderna made up 0.03% of Invesco's portfolio in Q2 2026, its #441 holding.
- Invesco first reported a position in Moderna in Q1 2019 and has held it in 30 quarters since.
- Invesco's Moderna position peaked at $446M in Q4 2021.
- 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.
Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.